Jun 17, 2009
While the Obama administration's getting serious about healthcare reform, it's time for a rather pointed reading comprehension test.
Consider the following story and find, if you can, the obvious problem:
The Swiss drug company Novartis will not give free vaccines against H1N1 flu to poor countries -- it will only consider discounts.
Novartis's refusal comes in the wake of a request from the Director General of the World Health Organization, Dr. Margaret Chan, who has called for drug companies to show solidarity with poor countries as they develop vaccines against the H1NI or "swine flu" pandemic.
Just by way of reminder, H1N1 has infected around 30,000 people globally, mostly in North America, though there have been a few deaths outside Mexico and the United States. Europe suffered its first death on Sunday. The first has just been reported in Argentina.
Help the poor prevent a pandemic? Novartis said 'No'. That's Novartis --makers of Exedrin and Bufferin -- I guess they haven't made enough off those over-the-counter best-sellers.
"If you want to make production sustainable, you have to create financial incentives," explained Novartis Chief Executive Daniel Vasella.
By "financial incentives" he means the 'p' word: profits.
Spot the flaw in the profit-driven approach to health care? Anyone?
Financial incentives?
When a pandemic isn't incentive enough -- I'd say we have another 'p' word -- a problem.
© 2023 GRITtv
Laura Flanders
Laura Flanders interviews forward-thinking people about the key questions of our time on The Laura Flanders Show, a nationally syndicated radio and television program also available as a podcast. A contributing writer to The Nation, Flanders is also the author of six books, including "Bushwomen: How They Won the White House for Their Man" (2005). She is the recipient of a 2019 Izzy Award for excellence in independent journalism, the Pat Mitchell Lifetime Achievement Award for advancing women's and girls' visibility in media, and a 2020 Lannan Cultural Freedom Fellowship for her reporting and advocacy for public media. lauraflanders.org
While the Obama administration's getting serious about healthcare reform, it's time for a rather pointed reading comprehension test.
Consider the following story and find, if you can, the obvious problem:
The Swiss drug company Novartis will not give free vaccines against H1N1 flu to poor countries -- it will only consider discounts.
Novartis's refusal comes in the wake of a request from the Director General of the World Health Organization, Dr. Margaret Chan, who has called for drug companies to show solidarity with poor countries as they develop vaccines against the H1NI or "swine flu" pandemic.
Just by way of reminder, H1N1 has infected around 30,000 people globally, mostly in North America, though there have been a few deaths outside Mexico and the United States. Europe suffered its first death on Sunday. The first has just been reported in Argentina.
Help the poor prevent a pandemic? Novartis said 'No'. That's Novartis --makers of Exedrin and Bufferin -- I guess they haven't made enough off those over-the-counter best-sellers.
"If you want to make production sustainable, you have to create financial incentives," explained Novartis Chief Executive Daniel Vasella.
By "financial incentives" he means the 'p' word: profits.
Spot the flaw in the profit-driven approach to health care? Anyone?
Financial incentives?
When a pandemic isn't incentive enough -- I'd say we have another 'p' word -- a problem.
Laura Flanders
Laura Flanders interviews forward-thinking people about the key questions of our time on The Laura Flanders Show, a nationally syndicated radio and television program also available as a podcast. A contributing writer to The Nation, Flanders is also the author of six books, including "Bushwomen: How They Won the White House for Their Man" (2005). She is the recipient of a 2019 Izzy Award for excellence in independent journalism, the Pat Mitchell Lifetime Achievement Award for advancing women's and girls' visibility in media, and a 2020 Lannan Cultural Freedom Fellowship for her reporting and advocacy for public media. lauraflanders.org
While the Obama administration's getting serious about healthcare reform, it's time for a rather pointed reading comprehension test.
Consider the following story and find, if you can, the obvious problem:
The Swiss drug company Novartis will not give free vaccines against H1N1 flu to poor countries -- it will only consider discounts.
Novartis's refusal comes in the wake of a request from the Director General of the World Health Organization, Dr. Margaret Chan, who has called for drug companies to show solidarity with poor countries as they develop vaccines against the H1NI or "swine flu" pandemic.
Just by way of reminder, H1N1 has infected around 30,000 people globally, mostly in North America, though there have been a few deaths outside Mexico and the United States. Europe suffered its first death on Sunday. The first has just been reported in Argentina.
Help the poor prevent a pandemic? Novartis said 'No'. That's Novartis --makers of Exedrin and Bufferin -- I guess they haven't made enough off those over-the-counter best-sellers.
"If you want to make production sustainable, you have to create financial incentives," explained Novartis Chief Executive Daniel Vasella.
By "financial incentives" he means the 'p' word: profits.
Spot the flaw in the profit-driven approach to health care? Anyone?
Financial incentives?
When a pandemic isn't incentive enough -- I'd say we have another 'p' word -- a problem.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.